arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Candel Therapeutics, Inc.

CADL
$8.04 ▼ -1.00 (-11.12%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
27 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
26
Health
Poor
Bearish
auto_awesome

Analytical Summary

Candel Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $596.0M
Dividend Yield —
Revenue Growth None
Op. Margin —
ROIC -16.8% ↘
FCF / Share $-0.23 ↗
Trailing P/E —
Price / Book 4.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$31.00K
— 0.0% —
Net Income Profit after all expenses
$-38.91M
↓ -711.2% —
FCF / Share Free cash flow per share
$-0.23
↑ +22.4% —
Long-Term Debt Long-term obligations
$4.22M
↓ -37.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
12
Financial Health ↓
23
Cash Quality ↑
66

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 7 years · 27 quarters